We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Odyssey Thera Awarded 19th Patent for Drug Discovery and Re-Purposing Technologies
News

Odyssey Thera Awarded 19th Patent for Drug Discovery and Re-Purposing Technologies

Odyssey Thera Awarded 19th Patent for Drug Discovery and Re-Purposing Technologies
News

Odyssey Thera Awarded 19th Patent for Drug Discovery and Re-Purposing Technologies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Odyssey Thera Awarded 19th Patent for Drug Discovery and Re-Purposing Technologies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Odyssey Thera, Inc. has announced that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."

Claims granted in the patent broadly cover the application of contextual high-content assays to diverse biological events, and the use of these methods for novel drug discovery and drug re-indication.

The concept of utilizing drugs with well-established pharmacology and safety characteristics for a novel therapeutic focus - drug re-indication or "re-repurposing" - has been proposed as a solution for improving success rates of therapeutic development.

"This patent, in concert with our existing IP, provides unprecedented coverage of cellular signaling space," said John K. Westwick, Ph.D., Odyssey Thera President and CEO.

"Access to all target classes and pathways is essential for deciphering compound and target mechanisms. Technologies protected by this patent, combined with our proprietary strategies for expediting preclinical development, represent a unique platform for fast-tracking new therapeutic development."

Advertisement